EU signs deal to acquire 200mn doses of potential COVID-19 vaccine

EU signs deal to acquire 200mn doses of potential COVID-19 vaccine

By

Brussels: The European Commission announced on Wednesday that it has reached an agreement with a sixth pharmaceutical company, this time BioNTech-Pfizer, to retain another 200 million doses of potential coronavirus vaccines.

European Commission President Ursula von der Lehn said: “Whether it is Europeans at home or elsewhere in the world, our chances of developing and deploying safe and effective vaccines are higher than ever.”

“To defeat the coronavirus anywhere, we need to defeat it everywhere.”

Brussels has previously signed agreements with Sanofi-GSK, Johnson & Johnson, Curevac, Moderna and AstraZeneca. Once any company develops a safe and effective coronavirus vaccine, they are ready to quickly purchase doses.

EU Health Commissioner Stella Kyriakides said: “We are optimistic that among these candidates there will be a safe and effective vaccine against Covid-19 to help us overcome this pandemic. .”

BioNTech said in a statement that the agreement also includes the option of another 100 million doses.

If the laboratory successfully clears the various test stages, delivery can begin as early as the end of 2020.

“We have activated our supply chain, most importantly our site in Belgium, and are starting to manufacture so that our vaccine would be available as soon as possible, if our clinical trials prove successful and regulatory approval is granted” said Albert Bouria, chairman and chief executive of Pfizer.

Laboratories around the world are racing to produce vaccines to help end the worst health crisis in more than a century.

In the clinical trial phase with human volunteers, more than 200 candidate vaccines are currently being developed, of which about 20 are.

Countries have also been working hard to ensure that there are enough doses, even before the vaccine has been tested, the world’s wealthiest countries have made billions of dollars worth of reservations to ensure delivery.

Fearing that US President Donald Trump will pressure regulators to approve the vaccine before the November presidential election, the CEOs of nine companies, including BioNTech and Pfizer, this week Commit to “maintain the integrity of scientific procedures.”

The two companies have made it clear that they will only seek emergency authorization for the vaccine after it “provides safety and effectiveness through phase 3 clinical studies designed to meet the requirements of expert regulatory agencies such as the FDA”, the US Food and Drug Administration.

Leave a Comment

Your email address will not be published.

You may also like

Hot News